[1] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58(2): 71-96.  doi: 10.3322/CA.2007.0010
[2] 宋平平, 贾慧, 张百江. FDG-PET及PET-CT在肺癌中的应用价值. 肿瘤防治杂志, 2004, 11 (1): 103-106.  doi: 10.3969/j.issn.1673-5269.2004.01.034
[3] 张晓颖, 韩冰, 侯跃芳, 等. 非小细胞肺癌淋巴结分期的PET/CT准确性评价——Meta分析. 中国临床医学影像杂志, 2009, 20(3): 184-188.  doi: 10.3969/j.issn.1008-1062.2009.03.009
[4] 于丽娟, 锻玉, 梁秀艳, 等. 18F-FDG PET/CT显像在肺癌诊断及探查转移灶中的价值. 中国医学影像技术, 2007, 23(4): 605-607.
[5] Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage Ⅲa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg, 1993, 55(6): 1365-1373.  doi: 10.1016/0003-4975(93)91072-U
[6] Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradio-stherapy: correlation with histopathology. Lung Cancer, 2002, 35(2): 179-187.  doi: 10.1016/S0169-5002(01)00332-4
[7] Santo A, Genestreti G, Sava T, et al. Neo-adjuvant chemotherapy in non-small cell lung cancer(NSCLC). Ann Oncol, 2006, 17(Suppl 5): v55-v61.
[8] Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomog-raphy is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol, 2003, 21(7): 1285-1292.  doi: 10.1200/JCO.2003.07.054
[9] Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23(33): 8362-8370.  doi: 10.1200/JCO.2005.01.1189
[10] Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged Ⅲ a-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol, 1998, 9(11): 1193-1198.
[11] Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg, 2004, 78(6): 1903-1909.  doi: 10.1016/j.athoracsur.2004.06.102
[12] Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med, 2004, 25(Suppl 1): 3-10.
[13] Weber WA, Petersen V, Schmidt B, et al. Positron emission tomogra-phy in non small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 2003, 21(14): 2651-2657.  doi: 10.1200/JCO.2003.12.004
[14] Pöttgen C, Lecegrün S, Theegarten D, et al. Value of 18F-fluoro-2-de-oxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res, 2006, 12(1): 97-106.  doi: 10.1158/1078-0432.CCR-05-0510
[15] Goffin J, Baral S, Tu D, et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res, 2005, 11(16): 5928-5934.  doi: 10.1158/1078-0432.CCR-05-0130
[16] van den Boogaart V, de Langen A, Groen HJ, et al. A phase Ⅱ study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC): Predictive value of molecular imaging. J Clin Oncol, 2008, 26(15s): 8055.
[17] Yamamoto Y, Kameyama R, Murota M, et al. Early assessment of thera-peutic response using FDG PET in small cell lung cancer. Mol Imaging Biol, 2009, 11(6): 467-472.  doi: 10.1007/s11307-009-0227-y
[18] Fischer BM, Mortensen J, Langer SW, et al. PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer, 2006, 54(1): 41-49.  doi: 10.1016/j.lungcan.2006.06.012
[19] Spaepen K, Stroobants S, Dupont P, et al. [18F]FDG PET monitoring of tumour response to chemotherapy: does[18F]FDG uptake correlate with the viable tumour cell fraction. Eur J Nucl Med Mol Imaging, 2003, 30(5): 682-688.  doi: 10.1007/s00259-003-1120-6
[20] Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation of FDG whole body PET studies in multi-center trials. Eur J Nucl Med Mol Imaging, 2008, 35(12): 2320-2333.  doi: 10.1007/s00259-008-0874-2
[21] Minn H, Zasadny KR, Quint LE, et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology, 1995, 196 (1): 167-173.  doi: 10.1148/radiology.196.1.7784562
[22] Weber WA, Ziegler SI, Thödtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med, 1999, 40 (11): 1771-1777.
[23] Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg, 2004, 77(1): 254-259.  doi: 10.1016/S0003-4975(03)01457-7